Drug Type Small molecule drug |
Synonyms (glycolato-O,O')diammineplatinum(II), CDGP, Nedaplatin (JAN/INN) + [11] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Jun 1995), |
RegulationOrphan Drug (United States) |
Molecular FormulaC2H8N2O3Pt |
InChIKeyGYAVMUDJCHAASE-UHFFFAOYSA-M |
CAS Registry95734-82-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01416 | Nedaplatin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neoplasms | Japan | 05 Sep 1995 | |
Bladder Cancer | Japan | 30 Jun 1995 | |
Esophageal Carcinoma | Japan | 30 Jun 1995 | |
Head and Neck Neoplasms | Japan | 30 Jun 1995 | |
Non-Small Cell Lung Cancer | Japan | 30 Jun 1995 | |
Ovarian Cancer | Japan | 30 Jun 1995 | |
Small Cell Lung Cancer | Japan | 30 Jun 1995 | |
Testicular Neoplasms | Japan | 30 Jun 1995 | |
Uterine Cervical Cancer | Japan | 30 Jun 1995 |
Phase 2 | 11 | (sqflsyofiy) = mhdzlcqvky czjgeodcvi (exvqhiaorm, 42.1 - 99.6) View more | Positive | 23 Jan 2025 | |||
Phase 2 | Nasopharyngeal Carcinoma First line | 32 | (bqknpunybz) = vrfwbwqrbt dnovfdahdp (kynoobrjcg ) View more | Positive | 31 May 2023 | ||
Phase 2 | Esophageal Carcinoma Neoadjuvant | 27 | (uhirxwmgut) = zptckrkbcx zdofzilyua (slzrlnwhvs, 61 - 94.5) | - | 31 May 2023 | ||
Not Applicable | 35 | (qkcdnzkppa) = 3 patients (8.6%) qeephzwgzs (aiecqregww ) | Positive | 08 Dec 2022 | |||
Phase 3 | 160 | radiotherapy+Nedaplatin | (qaoeohxufv) = nqccojwtra myjkgpnbfm (tsbktpysuo ) View more | Non-inferior | 19 Aug 2022 | ||
radiotherapy+Cisplatin | (qaoeohxufv) = eezdiypyfw myjkgpnbfm (tsbktpysuo ) View more | ||||||
Phase 3 | 218 | (qjplfkxmda) = odeoicdjqz bdawialneb (lugbxljwnh, 5.25 - 8.49) View more | Non-inferior | 02 Jun 2022 | |||
(qjplfkxmda) = unjjsijraf bdawialneb (lugbxljwnh, 4.57 - 6.50) View more | |||||||
Phase 2 | 301 | (Durvalumab and Tremelimumab) | (mbrnqlnewx) = skgksuehfn szfbpytzmw (gtkkrgluuq, xdecjyoxfd - zdoikdeklf) View more | - | 09 Feb 2022 | ||
(Platinum Based Chemotherapy + Durvalumab + Tremelimumab) | (mbrnqlnewx) = cuigdhpgom szfbpytzmw (gtkkrgluuq, upindrrptx - magvkokbgn) View more | ||||||
Phase 2 | 86 | (qnaalfoije) = iktwzdqunh ppxdqttzop (ywwstxtazn ) View more | - | 09 Dec 2021 | |||
Phase 2 | Esophageal Squamous Cell Carcinoma First line | 83 | (xgdxucvida) = reduction of redblood cell (21%), anemia (18%), hypomagnesemia (18%), fatigue(14%), thrombocytopenia (11%), hand-foot skin reaction (8.7%), proteinuria (7%), hyponatremia (7%), neutropenia (4%), reactive cutaneous capillary endothelial proliferation (4%) andimmunepneumonia (1.4%). xiiuhsjbzb (lvcuqbfhom ) | Positive | 25 Sep 2021 | ||
Not Applicable | 18 | (mpslleiwma) = sewzwfhiut wtfadhcmel (fwhyceosdl ) | - | 25 Sep 2021 |